Abstract
RWE is becoming increasingly accepted by healthcare stakeholders (e.g., regulators, payers, providers, patients, patient advocacy groups) to support decision-making across the product drug development lifecycle. However, it is unclear how the value and utility of RWE is perceived cross-functionally by EBPs. The objective of this survey was to assess baseline RWE knowledge of varied personnel representing medical and clinical affairs at an EBP and identify key learning opportunities to leverage RWE and optimize execution in the product development lifecycle.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
